You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華東醫藥(000963.SZ):Ellansé®伊妍仕®M型已順利完成中國臨牀試驗全部受試者入組,正在進行隨訪
格隆匯 01-18 17:20

格隆匯1月18日丨華東醫藥(000963.SZ)於2024年1月18日接受投資者調研,就“公司國內醫美最新的註冊及臨牀進展?”,公司回覆稱,Ellansé®伊妍仕®M型已順利完成中國臨牀試驗全部受試者入組,正在進行隨訪,預計於2024年第二季度完成全部受試者主要療效指標收集;MaiLi系列產品MaiLi Extreme在中國的註冊臨牀試驗預計於2024年第一季度完成全部受試者隨訪;MaiLi Precise於2023年12月順利完成中國臨牀試驗首例受試者入組;V20的註冊申請於2023年9月獲得國家藥監局器審中心受理,有望於2024年獲批上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account